Mouse Leptomeninges | ×102a | (ΔCt)b | Human Arachnoid | ×103c | Examples of Human Substrates/Ligands | ||
---|---|---|---|---|---|---|---|
Mouse LM | Mouse CP | Mouse Brain | |||||
L-Ptgds | 73.4 | −6.01 (1) | 1.34 (1) | 1.75 (1) | L-PTGDS | 1371 | |
Beta-actin | 59.1 | Zona Occludens 1 | 78.2 | ||||
Slc16a1/Mct1 | 27.9 | CYP1B1 | 73.4 | Retinal, arachidonic acid | |||
Slco1c1/Oatp-f | 17.3 | CYP4A11 | 38.8 | Fatty acids (medium chain) | |||
Cyp1b1 | 12.9 | 2.63 (4) | 7.04 (4) | 9.38 (7) | ABCB1/MDR1 | 28.5 | Hydrocortisone |
Slc22a6/Oat1 | 10.9 | 0.28 (2) | 8.30 (6) | 10.25 (8) | SLC22A2/OCT1 | 24 | Nucleoside analogs |
Abcg2/Bcrp | 10.8 | 3.22 (5) | 7.61 (5) | 6.54 (2) | SLC22A6/OAT1 | 15.8 | Methotrexate |
Slc22a8/Oat3 | 9.2 | 1.80 (3) | 4.78 (2) | 7.61 (4) | SLC22A8/OAT3 | 6.9 | Methotrexate |
Abcb1a/Mdr1a | 6.2 | 3.89 (6) | 6.15 (3) | 7.58 (3) | CYP3A5 | 6.4 | Tacrolimus |
Abcc4/Mrp4 | 2.1 | 6.16 (7) | 8.49 (7) | 9.28 (6) | ABCG2/BCRP | 4.7 | Topotecan |
Slco1a4/Oatp2 | 1.6 | CYP2D6 | 4.4 | Tamoxifen | |||
Nr1i3/Car | 1.1 | 15.96 (9) | 12.60 (9) | 16.51 (9) | SLC16A1/MCT1 | 4.4 | Lactate, glucose |
Abcb6/Prp | 1.1 | ABCB6/PRP | 4.1 | Porphyrin | |||
Slc16a11/Mct11 | 0.9 | SLC19A1/RFC1 | 2.8 | Methotrexate | |||
Abcc1/Mrp1 | 0.9 | 7.18 (8) | 9.54 (8) | 8.43 (5) | SLC16A11 | 1.5 | Monocarboxylates |
Cyp2d22 | 0.6 | NR1I2/PXR | 1.2 | Rifampin | |||
Abcc3/Mrp3 | 0.2 | CYP2B6 | 1.2 | Cyclophosphamide |
↵a Mouse leptomeninges from day 2 neonates; mouse expression (normalized signal intensity values) <1.0 × 102 are considered low.
↵b The ΔCt (cycle threshold) values for genes of interest (rank order in parentheses) obtained from quantitative real-time polymerase chain reaction analysis of mouse leptomeninges (LM), choroid plexus (CP), and whole brain pooled from day 2 neonates.
↵c Human arachnoid membrane expression: average normalized signal intensity value from two normal human arachnoid membranes (Gene Expression Omnibus dataset GSE19727).